参附注射液联合人免疫球蛋白治疗川崎病的临床研究

Clinical study on Shenfu Injection combined with human immunoglobulin in treatment of kawasaki disease

目的探究参附注射液联合静注人免疫球蛋白治疗川崎病的临床疗效。方法选取2013年5月—2015年5月重庆市垫江县人民医院收治的川崎病患儿128例,随机分为对照组和治疗组,每组各64例。两组患儿均给予常规治疗,对照组在常规治疗的基础上静脉滴注静注人免疫球蛋白(pH4),2 g/kg,1次输注;治疗组在对照组的基础上静脉滴注参附注射液,4 mL加到5%葡萄糖溶液100 mL,1次/d。两组患儿均治疗15 d。治疗后,观察两组的临床疗效,同时比较两组血常规、退热时间、住院时间、红细胞沉降率以及C反应蛋白变化情况。结果治疗后,对照组和治疗组的总有效率分别为76.6%、92.2%,两组比较差异有统计学意义(P<0.05)。治疗后,两组患儿的白细胞明显降低,而血小板和血红蛋白均明显升高,同组治疗前后差异有统计学意义(P<0.05);且治疗组治疗后这些观察指标的改善程度明显优于对照组,两组比较差异具有统计学意义(P<0.05)。治疗后,治疗组退热时间和住院时间明显短于对照组,两组比较差异具有统计学意义(P<0.05)。治疗后,两组患儿的红细胞沉降率和C-反应蛋白均显著下降,同组治疗前后差异有无统计学意义(P>0.05);且治疗组治疗后这些观察指标改善程度明显优于对照组,两组比较差异具有统计学意义(P<0.05)。结论参附注射液联合静注人免疫球蛋白治疗川崎病具有较好的临床疗效,能改善患儿血液学指标,缩短住院时间,具有一定的临床推广应用价值。

Objective To investigate the clinical effect of Shenfu Injection combined with Human Immunoglobulin（pH 4） for intravenous injection in treatment of kawasaki disease. Methods Children（128 cases） with kawasaki disease in Dianjiang People＇s Hospital of Chongqing from May 2013 to May 2015 were divided into the control and treatment groups, and each group had 64 cases. Children in two groups were given conventional therapy. Children in the control group were iv administered with Human Immunoglobulin（p H 4） for intravenous injection on the basis of the conventional therapy, 2 g/kg, only once. Children in the treatment group were iv administered with Shenfu Injection on the basis of the control group, 4 mL added into 5% glucose 100 mL, once daily. Children in two groups were treated for 15 d. After treatment, the efficacies were evaluated, and routine blood, defervescence time, hospitalization time, erythrocyte sedimentation rate, and C-reactive protein in two groups were compared. Results After treatment, the clinical efficacies in the control and treatment groups were 76.6% and 92.2%, respectively, and there was difference between two groups（P〈 0.05）. After treatment, white cells in two groups was significantly decreased, but platelets and hemoglobin in two groups were significantly increased, and the difference was statistically significant in the same group（P〈 0.05）. And the observational indexes in the treatment group were significantly better than those in the control group, with significant difference between two groups（P〈 0.05）. After treatment, defervescence time and hospitalization time in the treatment group were obviously shorter than those in the control group, and there was difference between two groups（P〈 0.05）. After treatment, erythrocyte sedimentation rate and C-reactive protein in two groups were significantly decreased, and the difference was statistically significant in the same group（P〈 0.05）. And the observational indexes in the treatment group were significantly better than those in the control group, with significant difference between two groups（P〈 0.05）. Conclusion Shenfu Injection combined with Human Immunoglobulin（p H 4） for intravenous injection has clinical curative effect in treatment of kawasaki disease, and can improve hematological indexes, shorten hospitalization time, which has a certain clinical application value.